Biogen, Inc. (BIIB)
$278.14
6.07 (2.14%)
BIIB Stock Quote Delayed 15 Minutes
Previous Close
$278.14
Market Cap
58.69B
PE Ratio
19.87
EPS
14
Volume (Avg. Vol.)
1.26M
Day's Range
277.32 - 284.99
52-Week Range
215.77 - 338.87
Dividend & Yield
N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
3 Big Stock Charts for Wednesday: Biogen, Cooper Companies, and Maxim
Wednesday's big stock charts highlight 3 stocks looking to break through resistance in a market that looks a bit shaky at the moment.
5 Top Stock Trades for Friday: RH, DG, KR, BIIB
RH, Dollar General, Kroger, Biogen and Signet Jewelers were our top stock trades for Friday. Let's look at the charts.
The Good, Bad, and Ugly for Biogen Stock
With news that Biogen’s Alzheimer’s drug was allowed to reapply for possible FDA approval, Biogen stock skyrocketed. However, investors will want to carefully consider all angles before jumping onboard.
Wednesday’s Vital Data: Biogen, McDonald’s and Lyft
Options trading was buzzing in Biogen, McDonald's and Lyft stock on Tuesday. Here are the metrics that matter moving forward.
Stock Market Today: Biogen’s Answer to Alzheimer’s
Biogen erupted in early trading, as it seeks approval for its Alzheimer's treatment. Here's what happened in the stock market today.
Stock Market Today: Stocks Rally Ahead of Big Earnings Week
Another opioid settlement has been reached and earnings season is heating up. Here's what happened in the stock market today.
3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat
Biogen earnings for the second quarter of the year have BIIB stock heading higher on Tuesday thanks to a strong EPS and revenue beat.
MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock
The owners of Biogen stock will examine Biogen earnings to asss the progress that BIIB is making in key areas, including Ms and Spinraza.
Nasdaq Today: Biotech Wrecked; Buy Microsoft?
Investors saw new highs in the Nasdaq today, but the index finished slightly lower on the day. Here's what we're watching now.
Nasdaq Today: Apple Loses Ive and the Nasdaq’s Q3 Outlook
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
Nasdaq Today: Hard to Keep Track of the Losers
Biotech rallied on a $63 billion deal between AbbVie and Allergan. But other than that, it was a tough day for the Nasdaq today.
Nasdaq Today: Maintaining Altitude Amid Uncertainty
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
